RGNT
Regentis Biomaterials Ltd. (AMEX)
Healthcare — Medical Instruments & Supplies
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
None
1 analysts
$4.03
$-0.54 (-11.82%)
Target:
$10.00
(148.1%)
Sign in to add RGNT to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $32.16M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-24.16 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 25.23 |
| Recommendation | None |
| Analyst Target | $10.00 |
| Analysts | 1 |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 59.1 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.50 |
| 52-Week Low | $1.23 |
| 50-Day Avg | $2.83 |
| 200-Day Avg | $4.22 |
| Avg Volume | $5.36M |
| Volume | 157.8K |
Performance Analysis
BULLISHRGNT shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 20% of its 52-week range.
+
RSI at 59.1 shows positive momentum.
~
Wall Street consensus is "none" from 1 analysts.
+
Average analyst target of $10.00 implies 148.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report